Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Leukemia

290 clinical trials

312 products

59 drugs

Product
Ruxolitinib
Product
Asparaginase Erwinia Chrysanthemi
Clinical trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Product
Leucovorin
Product
Vincristine
Product
Dexamethasone
Product
Doxorubicin
Product
Methotrexate
Product
Pegaspargase
Product
Prednisone
Product
Thioguanine
Product
Mercaptopurine
Product
Cyclophosphamide
Product
Cytarabine
Clinical trial
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D and Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (HR-MDS)
Status: Active (not recruiting), Estimated PCD: 2024-03-04
Clinical trial
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Status: Terminated, Estimated PCD: 2024-02-13
Product
H3B-8800
Product
Decitabine
Product
BI 836858
Clinical trial
An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia
Status: Completed, Estimated PCD: 2023-01-16
Product
GSK3745417
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2026-06-14
Product
Azacitidine
Product
AG-120
Clinical trial
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2018-08-02
Product
DSP-5336
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Status: Recruiting, Estimated PCD: 2025-01-02
Product
fadraciclib
Clinical trial
A Long-term Follow-up Study of Patients Who Received VOR33
Status: Recruiting, Estimated PCD: 2040-01-01
Clinical trial
A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML)
Status: Completed, Estimated PCD: 2024-01-08
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Status: Active (not recruiting), Estimated PCD: 2019-07-15
Product
Placebo
Product
CC-486
Product
Venetoclax
Clinical trial
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Status: , Estimated PCD: 2024-10-01
Product
AG-221
Product
Oral Azacitidine
Product
VOR33
Product
Pirtobrutinib
Clinical trial
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Status: Recruiting, Estimated PCD: 2028-03-24
Product
Ibrutinib
Product
CC-95251
Clinical trial
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Status: Recruiting, Estimated PCD: 2024-12-07
Product
Ponatinib
Clinical trial
A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
CC-90009
Clinical trial
An Exploratory Phase 1b Open-label Multi-arm Trial to Evaluate the Safety and Efficacy of CC-90009 in Combination With Anti-Leukemia Agents in Subjects With Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-10-25
Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
Pelabresib
Product
Gilteritinib
Product
MP0533
Product
enasidenib
Product
Arm 1 probes
Product
Arm 2 Probes
Product
Arm 3 probes
Clinical trial
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Status: Completed, Estimated PCD: 2020-06-08
Clinical trial
A Phase 1, 2-Part, Multicenter, Open-Label, 3-Arm Study to Determine the Effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Oral Doses of Caffeine, Dextromethorphan, Fexofenadine, Flurbiprofen, Midazolam, Omeprazole, Pioglitazone, and Rosuvastatin in Patients With Acute Myeloid Leukemia
Status: Completed, Estimated PCD: 2023-09-22
Product
Efprezimod alfa
Product
Leucovorin Calcium
Product
Efprezimod
Product
Tacrolimus
Product
MGD024
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Oral decitabine/cedazuridine
Clinical trial
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
Status: Recruiting, Estimated PCD: 2027-08-27
Product
Asciminib
Product
Imatinib
Product
Nilotinib
Product
Bosutinib
Product
Dasatinib
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission
Status: Recruiting, Estimated PCD: 2025-01-03
Clinical trial
A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2026-05-05
Clinical trial
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Recruiting, Estimated PCD: 2025-04-01
Product
CC-91633
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2025-01-15
Product
INS19 CAR-T Cells
Product
Oral decitabine/Cedazuridine
Product
Oral Decitabine + Cedazuridine
Clinical trial
Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Status: Completed, Estimated PCD: 2019-07-17
Product
Vincrisitne
Product
Blinatumomab
Product
Daunorubicin
Product
Ifosfamide
Product
PEG-asparaginase
Product
Erwinia-asparaginase
Product
DS-3201b
Clinical trial
A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Status: Terminated, Estimated PCD: 2021-03-09
Clinical trial
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2025-03-01
Product
BG1805
Clinical trial
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Product
Oral decitabine + Cedazuridine
Product
Arm 3 Probes
Clinical trial
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Completed, Estimated PCD: 2020-11-12
Product
ibrutinib
Product
venetoclax
Clinical trial
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Mylotarg
Clinical trial
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) With or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults With Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission With Minimal Residual Disease (MRD) or Relapsed/Refractory (R/R) AML
Status: Recruiting, Estimated PCD: 2024-06-03
Product
VCAR33
Clinical trial
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients With Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-30
Product
BGB-11417
Clinical trial
A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Status: Completed, Estimated PCD: 2023-05-03
Clinical trial
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Guadecitabine
Product
Liposomal Annamycin
Clinical trial
A Phase II Study to Determine the Activity of Dasatinib Administered Orally (PO) at a Dose of 100 mg Once Daily (QD) in Chronic Phase Chronic Myelogenous Leukemia (CML), at a Dose of 70 mg Twice Daily (BID) in Advanced Phase Chronic Myelogenous Leukemia (CML) Chinese Subjects Who Are Resistant to or Intolerant of Imatinib Mesylate (Gleevec®)
Status: Completed, Estimated PCD: 2009-06-17
Product
Clifutinib
Clinical trial
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
Status: Recruiting, Estimated PCD: 2026-02-10
Product
Ara-C±IDA
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents
Status: Completed, Estimated PCD: 2020-03-31
Clinical trial
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy
Status: Terminated, Estimated PCD: 2022-06-16
Product
ABT-199
Product
CYNK-001
Product
Posaconazole
Product
LOXO-338
Product
LoDAC
Product
FLAG-IDA
Clinical trial
A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)
Status: Completed, Estimated PCD: 2018-12-31
Product
Durvalumab
Clinical trial
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Induction Therapy
Status: Completed, Estimated PCD: 2022-02-08
Clinical trial
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2023-04-10
Clinical trial
A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Status: Completed, Estimated PCD: 2022-08-11
Product
LOXO-305
Product
CD123 CAR-T cells
Clinical trial
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Status: Recruiting, Estimated PCD: 2022-12-01
Product
ETH-155008
Clinical trial
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
Status: Completed, Estimated PCD: 2021-03-19
Product
Docetaxel
Clinical trial
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
Status: Terminated, Estimated PCD: 2023-05-02
Clinical trial
A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Status: Completed, Estimated PCD: 2022-01-25
Product
Pevonedistat
Clinical trial
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Terminated, Estimated PCD: 2023-05-04
Product
BMS-986403
Product
Paclitaxel
Clinical trial
A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia
Status: Completed, Estimated PCD: 2021-11-04
Product
DFP-10917
Clinical trial
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2023-12-31
Product
CD19 and CD22 targeted CAR-T cells
Product
Fludarabine
Product
Carboplatin
Clinical trial
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Status: Completed, Estimated PCD: 2009-01-19
Product
Volasertib
Clinical trial
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2023-08-15
Clinical trial
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia
Status: Completed, Estimated PCD: 2012-03-09
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-67371244 (Bispecific Antibody Targeting CD33 and CD3), in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-03-26
Product
Mitoxantrone
Clinical trial
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Product
COVID-19 Vaccine
Clinical trial
Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor
Status: Recruiting, Estimated PCD: 2023-01-26
Clinical trial
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia
Status: Completed, Estimated PCD: 2019-09-04
Product
JNJ-67571244
Clinical trial
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia
Status: Not yet recruiting, Estimated PCD: 2023-08-01
Product
CAR-T
Clinical trial
A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo
Status: Completed, Estimated PCD: 2018-10-03
Product
Sprycel Dasatinib
Clinical trial
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
CD19 CAR-T cells
Product
CD19 and CD22 Targeted CAR-T Cells
Product
ARGX-110
Product
AZA
Clinical trial
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Status: Completed, Estimated PCD: 2016-05-01
Clinical trial
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Phase 1/2 Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2024-02-28
Clinical trial
An Open Label, Single-arm, Phase I Study of JWCAR029 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Withdrawn, Estimated PCD: 2023-01-31
Clinical trial
A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
Status: Completed, Estimated PCD: 2021-07-19
Product
CD123 targeted CAR-NK cells
Clinical trial
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status: Active (not recruiting), Estimated PCD: 2016-09-01
Clinical trial
Characteristics, Treatment Patterns, and Clinical Outcomes in Non-intensive Chemotherapy Acute Myeloid Leukemia (AML) Patients - a US Real-World Study Using Electronic Medical Record Data
Status: Withdrawn, Estimated PCD: 2021-03-31
Product
glasdegib
Clinical trial
A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE
Status: Completed, Estimated PCD: 2022-09-21
Product
Cusatuzumab
Product
Iomab-B
Clinical trial
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Product
ASN002
Clinical trial
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2018-06-01
Product
Conventional Care
Clinical trial
A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia
Status: Completed, Estimated PCD: 2019-03-06
Clinical trial
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
Status: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units
Status: Active (not recruiting), Estimated PCD: 2009-11-11
Drug
Filgrastim
Product
Busulfan
Drug
cyclophosphamide
Product
Cyclosporine
Drug
Melphalan
Product
Mycophenolate Mofetil
Clinical trial
A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Chimeric antigen receptor T cells
Clinical trial
A Phase I Study of Venetoclax Combined With Vyxeos (CPX-351) for Children, Adolescents and Young Adults With Relapsed or Refractory Acute Leukemia
Status: Recruiting, Estimated PCD: 2025-01-01
Drug
CPX-351
Clinical trial
Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Blinatumomab Maintenance Treatment
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Drug
blinatumomab
Clinical trial
Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Kappa CD28 T cells
Clinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Status: Active (not recruiting), Estimated PCD: 2021-11-08
Clinical trial
Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Status: Not yet recruiting, Estimated PCD: 2029-07-01
Product
Autologous HuCD19 (Anti-CD19)CAR T cells
Product
Peptide Specific Dendritic Cell
Drug
Varlilumab
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan
Status: Completed, Estimated PCD: 2019-05-30
Drug
rituximab
Product
melphalan
Drug
sirolimus
Drug
tacrolimus
Clinical trial
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Status: Terminated, Estimated PCD: 2012-01-10
Drug
R-CHOP
Drug
Vincristine
Product
Hydrocortisone
Clinical trial
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Status: Completed, Estimated PCD: 2021-08-28
Drug
Carfilzomib
Product
Etoposide
Clinical trial
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Bisantrene
Product
Clofarabine
Clinical trial
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2026-10-05
Product
Mini-hyper CVD
Clinical trial
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)
Status: Not yet recruiting, Estimated PCD: 2026-05-01
Product
Treatment Arm A
Clinical trial
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Status: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
Elucidation of Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide (PTCy) as a Strategy for Graft Versus Host Disease Prevention in Haploidentical, Matched Related Donor and Matched Unrelated Donor Peripheral Blood Hematopoietic Cell Transplantation
Status: Recruiting, Estimated PCD: 2033-10-01
Clinical trial
A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-06-09
Clinical trial
A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML
Status: Not yet recruiting, Estimated PCD: 2026-03-02
Product
Revumenib
Product
Midostaurin
Product
Thiotepa
Drug
fludarabine
Clinical trial
Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells
Clinical trial
A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2026-04-30
Product
Standard Chemotherapy
Clinical trial
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Status: Completed, Estimated PCD: 2023-01-24
Product
Alemtuzumab
Drug
Tocilizumab
Clinical trial
Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2006-09-01
Product
RAD001
Clinical trial
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Status: Recruiting, Estimated PCD: 2027-09-20
Drug
decitabine
Product
spartalizumab
Product
sabatolimab
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy
Status: Completed, Estimated PCD: 2020-09-22
Product
Thymoglobulin
Product
Idarubicin
Product
Cladribine
Clinical trial
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Status: Terminated, Estimated PCD: 2020-06-01
Product
BPX-501
Product
Rimiducid
Product
Anti-CD19-CAR
Clinical trial
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Status: Completed, Estimated PCD: 2021-08-13
Product
Chemotherapy
Product
Quizartinib
Clinical trial
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy
Status: Terminated, Estimated PCD: 2022-03-09
Product
CC-90011
Clinical trial
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Status:
Product
EPZ-5676
Product
CART-19/22
Product
rivogenlecleucel
Product
JWCAR029
Clinical trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Status: , Estimated PCD: 2027-07-02
Clinical trial
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Status: Terminated, Estimated PCD: 2020-06-30
Clinical trial
Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-05-15
Product
Inotuzumab ozogamicin
Clinical trial
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2025-02-01
Product
CC-96191
Clinical trial
A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Status: Active (not recruiting), Estimated PCD: 2023-04-11
Product
azacitidine
Product
Lenalidomide
Product
Rituximab
Product
Bendamustine
Product
Ascentage Pharma HQP1351
Clinical trial
Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)
Status: Active (not recruiting), Estimated PCD: 2016-05-30
Drug
etoposide
Clinical trial
Blinatumomab Prevents the Recurrence of Relapsed or Refractory Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem-cell Transplantation: A Prospective, Singlecentered, Single-arm, Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Dependent Versus Best Supportive Care (BSC) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Independent
Status: Active (not recruiting), Estimated PCD: 2026-10-30
Clinical trial
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Status: Recruiting, Estimated PCD: 2027-06-30
Product
Vincristine + Dexamethasone
Product
Inotuzumab Ozogamicin
Product
6-Tioguanine
Clinical trial
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Product
Amsacrine
Product
Methylprednisolone
Clinical trial
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine
Status: Completed, Estimated PCD: 2023-05-25
Product
mRNA-1273
Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Status: Active (not recruiting), Estimated PCD: 2021-03-18
Drug
Ivosidenib
Clinical trial
CD19-directed CAR-T Cell Therapy for Refractory or Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma: a Multicenter Phase I/II Trial.
Status: Not yet recruiting, Estimated PCD: 2028-10-01
Drug
Tisagenlecleucel
Product
EZN-3042
Clinical trial
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Status: Completed, Estimated PCD: 2024-04-30
Clinical trial
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
Status: Terminated, Estimated PCD: 2023-04-03
Product
Copanlisib
Product
Calaspargase Pegol
Clinical trial
A Multi-center, Prospective, Single-arm Study of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia (R/R AML)
Status: Recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia
Status: Terminated, Estimated PCD: 2016-08-01
Product
Brentuximab Vedotin
Product
5-Azacytidine
Clinical trial
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Short-term Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-cell Acute Lymphoblastic Leukemia With Low Leukemia Burden
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2011-03-01
Product
CD3-depleted/CD56+ selected natural killer cells
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Status: Active (not recruiting), Estimated PCD: 2024-09-17
Product
Sabatolimab
Clinical trial
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission (ALERT CML)
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Ascimininb + Nilotinib
Product
Asciminib + Imatinib
Product
Asciminib + Dasatinib
Clinical trial
Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy
Status: Completed, Estimated PCD: 2018-12-19
Clinical trial
A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Status: Completed, Estimated PCD: 2020-03-17
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Status: Active (not recruiting), Estimated PCD: 2023-09-13
Product
CD19- and CD22 specific CAR
Clinical trial
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Low-dose cytarabine
Product
Intermediate-dose cytarabine
Clinical trial
Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
Status: Completed, Estimated PCD: 2012-03-01
Drug
Erlotinib
Drug
azacitidine
Drug
venetoclax
Product
INQOVI
Clinical trial
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2027-07-01
Product
CD19/CD22-CAR-transduced T cells
Product
Stem Cell Infusion
Product
Mycophenolate mofetil
Clinical trial
Phase I/II Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Status: Terminated, Estimated PCD: 2017-04-12
Product
Moxetumomab Pasudotox
Clinical trial
A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-11-25
Product
JNJ-67856633
Clinical trial
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Status: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Product
KIR
Product
HLA genotyping
Clinical trial
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Gene-modified T cells
Clinical trial
Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Status: , Estimated PCD: 2027-10-16
Clinical trial
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome
Status: Recruiting, Estimated PCD: 2025-12-01
Drug
busulfan
Product
cyclosporine
Drug
mycophenolate mofetil
Clinical trial
Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Pioglitazone
Product
Trametinib
Clinical trial
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy
Status: Recruiting, Estimated PCD: 2033-06-01
Product
Genomic profiling
Clinical trial
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders
Status: Active (not recruiting), Estimated PCD: 2007-03-13
Product
Fludarabine phosphate
Drug
methotrexate
Clinical trial
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Status: Recruiting, Estimated PCD: 2024-05-31
Drug
Ceralasertib
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Drug
doxorubicin
Clinical trial
A Phase II Study to Evaluate Safety and Efficacy of CB-103 in Combination With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)
Status: Recruiting, Estimated PCD: 2026-07-01
Product
CB-103
Clinical trial
A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine
Status: Completed, Estimated PCD: 2019-06-07
Clinical trial
A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Neratinib
Clinical trial
Phase 2 Clinical Trial With Ponatinib as a Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Prior First Line Tyrosine Kinase Inhibitor Treatment
Status: Terminated, Estimated PCD: 2023-02-28
Clinical trial
Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)
Status: Recruiting, Estimated PCD: 2028-03-01
Product
Itacitinib
Clinical trial
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Vemurafenib
Product
Obinutuzumab
Clinical trial
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Status: Recruiting, Estimated PCD: 2041-10-01
Product
Cryopreserved Cord Blood Units
Clinical trial
Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase II Single Arm Study of Cladribine, Cytarabine, Etoposide and Venetoclax Sequential With Reduced Dose Conditioning of Fludarabine, Busulfan and Melphalan or Total Marrow Radiation for Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2026-02-01
Product
CALGE-VEN-RIC
Clinical trial
Graft-Versus-Tumor Augmentation With Nivolumab for High-Risk Patients With MDS and AML After Allogeneic Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide
Status: Withdrawn, Estimated PCD: 2021-04-20
Drug
T-VEC
Clinical trial
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Prospective Comparison Between Prophylactic and On-demand Use of Tocilizumab in CAR-T Recipients - a Randomized, Two Arm, Open-label, Single-center Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
Tocilizumab
Clinical trial
Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years
Status: Completed, Estimated PCD: 2022-04-25
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Status: Recruiting, Estimated PCD: 2027-11-26
Product
JCAR017
Drug
etoposide
Clinical trial
Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
lenalidomide
Clinical trial
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
TURALIO(R)
Clinical trial
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Status: Active (not recruiting), Estimated PCD: 2022-06-30
Product
Lactobacillus plantarum strain 299
Product
Lactobacillus plantarum strain 299v
Clinical trial
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Status: Recruiting, Estimated PCD: 2025-04-25
Product
Valacyclovir
Drug
Allopurinol
Clinical trial
Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CD19CAT-41BBZ CAR T-cells
Clinical trial
Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin
Status: Completed, Estimated PCD: 2008-02-01
Product
Anti-Thymocyte Globulin
Clinical trial
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-03-08
Product
Anti-CD19-chimeric-antigen-receptor-transduced T cells
Clinical trial
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Status: Recruiting, Estimated PCD: 2027-12-31
Drug
Docetaxel
Product
Pegfilgrastim
Clinical trial
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory NHL or CLL
Status: Recruiting, Estimated PCD: 2027-12-01
Drug
ONO-7018
Clinical trial
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Status: Completed, Estimated PCD: 2010-09-01
Drug
cytarabine
Drug
dexamethasone
Clinical trial
Value of Chemokine Receptor CXCR4-targeting Molecular Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
Status: Recruiting, Estimated PCD: 2024-12-01
Product
68Ga-Pentixafor
Clinical trial
Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL)
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804
Status: , Estimated PCD: 2001-02-01
Product
Southern blotting
Product
Cytogenetic analysis
Product
Polymerase Chain Reaction
Clinical trial
A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Status: Active (not recruiting), Estimated PCD: 2021-02-26
Product
Chlorambucil
Clinical trial
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
CD19/CD22 CAR T-Cells
Clinical trial
Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Drug
aldesleukin
Product
filgrastim
Drug
idarubicin
Clinical trial
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Terminated, Estimated PCD: 2016-05-01
Clinical trial
A Pilot Safety Trial of STING-dependent Activators (STAVs) and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
Status: Withdrawn, Estimated PCD: 2025-11-30
Product
STING-Dependent Activators
Product
Dendritic Cell Vaccine
Clinical trial
IDH2-Post-Allo-Trial: Enasidenib as Consolidation or Salvage Therapy for Patients With IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
Enasidenib
Clinical trial
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)
Status: Completed, Estimated PCD: 2017-03-03
Clinical trial
(H-49235) Trivalent Autologous T-Lymphocytes Co-Expressing Three Chimeric Antigen Receptors Targeting CD19, CD20 AND CD22 in Acute B-lineage Leukemia (TRICAR-ALL)
Status: Recruiting, Estimated PCD: 2026-07-17
Product
Autologous TRICAR-ALL T-cells
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Product
SCRI-CAR22v2
Clinical trial
A Phase Ib Study of Oral Decitabine/Cedazuridine as Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Patients With Myeloid Neoplasms
Status: Recruiting, Estimated PCD: 2023-08-24
Drug
ASTX727
Clinical trial
Venetoclax Combining Chidamide and Azacitidine (VCA) Regimen Followed by Dicitabine Combined With Liposome Mitoxantrone, Cytarabine, and G-CSF (D-MAG) Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) : A Multicenter, Prospective, Single Arm Clinical Trial
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Status: Completed, Estimated PCD: 2012-11-01
Clinical trial
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.
Status: Active (not recruiting), Estimated PCD: 2025-02-07
Product
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Clinical trial
Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2013-08-01
Clinical trial
A Phase 1/2a, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety and Efficacy of GDX012 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2026-04-01
Product
GDX012
Product
Chemotherapy Agents
Clinical trial
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
CPI-613
Clinical trial
Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)
Status: Terminated, Estimated PCD: 2022-07-28
Drug
sargramostim
Clinical trial
Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups
Status: Completed, Estimated PCD: 2019-04-04
Product
Caspofungin
Clinical trial
Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact
Status: Recruiting, Estimated PCD: 2025-06-01
Product
RNA-seq
Product
Whole Exon Sequencing
Product
Rabbit ATG
Clinical trial
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
PEG-Asparaginase
Product
6-MP
Drug
mFOLFOX6
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
Status: Active (not recruiting), Estimated PCD: 2025-04-04
Product
JNJ-75348780
Clinical trial
Administration of Donor-Derived Multi-Tumor-Associated Antigen (TAA)-Specific T Cells to Patients With ALL
Status: Active (not recruiting), Estimated PCD: 2019-10-29
Product
MultiTAA-specific T cells
Clinical trial
90Yttrium-labelled Anti-CD66 Monoclonal Antibody as Part of a Reduced Toxicity Conditioning Regimen Prior to Allogeneic Haematopoietic Stem Cell Transplantation: an Open Label, Phase II Study in Children and Adolescents With High Risk Leukaemia
Status: Recruiting, Estimated PCD: 2025-09-30
Product
90-Yttrium-labelled anti-CD66 monoclonal antibody
Clinical trial
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2026-04-06
Product
JNJ-64264681
Clinical trial
Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies
Status: Active (not recruiting), Estimated PCD: 2010-04-12
Clinical trial
To Evaluate Safety and Efficacy of Azacitidine Combination With Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients：A Multicenter, Single-arm Study
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study Assessing CPX-351 (Vyxeos™) With Quizartinib for the Treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML
Status: Terminated, Estimated PCD: 2021-04-20
Product
Peripheral Blood Stem Cell Transplant
Product
Allopurinol
Product
Bone Marrow Cell Transplant
Product
Sirolimus
Clinical trial
Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
Status: Completed, Estimated PCD: 2022-09-13
Product
Adult differentiated autologous T-cells
Clinical trial
A Phase I/II Study to Determine the Safety and Efficacy of Ruxolitinib, a JAK1/JAK2 Inhibitor, in Subjects With Relapsed or Refractory Acute Leukemia
Status: Terminated, Estimated PCD: 2012-07-01
Clinical trial
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
Status: Withdrawn, Estimated PCD: 2023-08-01
Product
Ziftomenib
Clinical trial
A Phase I Trial of Donor Enriched Activated NK (DEA-NK) Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
Status: Withdrawn, Estimated PCD: 2023-04-12
Product
Donor Enriched Activated Natural Killer Cell
Clinical trial
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL
Status: Recruiting, Estimated PCD: 2024-07-31
Product
JNJ-80948543
Clinical trial
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Recruiting, Estimated PCD: 2028-09-29
Clinical trial
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
Status: Completed, Estimated PCD: 2017-12-09
Product
pentostatin
Drug
alemtuzumab
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-02-08
Product
SCRI-huCAR19v1
Product
SCRI-huCAR19v2
Product
Polymorphism Analysis
Clinical trial
Search for an Association Between the Innate CD8+ T Cell Population and the Evolution of TKI (Tyrosine Kinase Inhibitor) Resistance Mutations in Phi+ Hematological Malignancies.
Status: Recruiting, Estimated PCD: 2024-07-01
Product
CD8+T cells phenotyping
Clinical trial
Multidrug Resistance Protein Gene Polymorphisms in Acute Myeloid Leukemia. A CALGB Leukemia Tissue Bank Project
Status: , Estimated PCD: 2100-01-01
Product
Gene Expression Analysis
Product
Molecular genetic technique
Product
Protein Expression Analysis
Clinical trial
A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
Status: Completed, Estimated PCD: 2012-04-12
Product
SB939
Clinical trial
PROSPECTIVE RANDOMISED STUDY TO COMPARE INTERFERON-ALPHA-n1 (WELLFERON) VS 'IDAC' CHEMOTHERAPY AND AUTOGRAFTING FOLLOWED BY INTERFERON ALPHA-n1 (WELLFERON) IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Status: , Estimated PCD: 2004-03-01
Product
Recombinant Interferon Alfa
Drug
hydroxyurea
Clinical trial
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Status: Active (not recruiting), Estimated PCD: 2022-09-19
Drug
prednisone
Clinical trial
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Status: Active (not recruiting), Estimated PCD: 2024-12-02
Clinical trial
Risk-adapted Therapy for Primary Acute Myeloid Leukemia (AML) in Adult Patients up to 70 Years Old
Status: Completed, Estimated PCD: 2022-07-31
Product
Ara-C
Clinical trial
A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS
Status: Completed, Estimated PCD: 2010-03-18
Clinical trial
Phase II Study of Theophylline in Chronic Lymphocytic Leukemia
Status: , Estimated PCD: 2002-09-01
Product
theophylline
Clinical trial
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response
Status: Recruiting, Estimated PCD: 2023-12-31
Drug
imatinib
Drug
nilotinib
Drug
dasatinib
Clinical trial
Next Generation Sequencing (NGS) Approach to Study Known and New Germline Mutations in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Analysis with molecular biology
Clinical trial
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess Blasts
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Talazoparib
Clinical trial
A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Status: Completed, Estimated PCD: 2005-10-01
Drug
gemtuzumab ozogamicin
Product
Liposomal Daunorubicin
Product
Topotecan
Clinical trial
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Status: Active (not recruiting), Estimated PCD: 2021-05-28
Clinical trial
A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts
Status: , Estimated PCD: 2009-06-01
Drug
GM-CSF
Product
Zosuquidar
Clinical trial
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Status: Active (not recruiting), Estimated PCD: 2018-09-17
Product
gilteritinib
Clinical trial
An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment
Status: Completed, Estimated PCD: 2019-11-21
Drug
pegfilgrastim
Product
Fluorescence in situ hybridization
Product
Mutation Analysis
Product
Protein expression analysis
Clinical trial
Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
The Efficacy and Safety of Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Status: Recruiting, Estimated PCD: 2024-10-10
Product
BCL2 Inhibitor plus IM2
Clinical trial
Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2019-04-02
Clinical trial
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2019-08-21
Product
CD45RA-depleted peripheral blood mononuclear cells
Clinical trial
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China
Status: Recruiting, Estimated PCD: 2026-03-30
Product
Sorafenib
Clinical trial
A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia
Status: Completed, Estimated PCD: 2022-03-07
Product
Eltrombopag
Clinical trial
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Status: Completed, Estimated PCD: 2021-04-06
Clinical trial
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes
Status: Completed, Estimated PCD: 2014-02-01
Product
Photopheresis
Product
Mycofenolate mofetil
Product
Pentostatin
Clinical trial
Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
Status: , Estimated PCD: 2018-05-18
Drug
bortezomib
Product
Pravastatin
Clinical trial
A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
Status: Recruiting, Estimated PCD: 2024-12-03
Product
Me-CCNU
Product
Rabbit antithymocyte globulin
Product
Cyclosporin A
Clinical trial
An Open, Multi-center, Randomized Trial Comparing Haploidentical HSCTs From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
Ofatumumab
Clinical trial
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study
Status: Completed, Estimated PCD: 2005-07-01
Drug
Ketamine
Drug
leucovorin
Product
mercaptopurine
Drug
pegaspargase
Product
thioguanine
Clinical trial
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Status: Completed, Estimated PCD: 2018-12-01
Clinical trial
Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical Trial
Status: Recruiting, Estimated PCD: 2026-02-28
Product
Cytokine Induced Memory-like Natural Killer Cells
Drug
interleukin-2
Clinical trial
Study of Venetoclax and Reduced-intensity Conditioning Regimen(RIC) for Allogeneic Stem Cell Transplantation(Allo-HSCT) in Elderly Patients With High-risk Myeloid Malignancies
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
nelarabine
Clinical trial
A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2024-05-03
Drug
Lurbinectedin
Clinical trial
A Phase 1b Study of JNJ-75276617 in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Status: Recruiting, Estimated PCD: 2024-05-15
Product
JNJ-75276617
Product
Daunorubicin or Idarubicin
Clinical trial
Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients: the PONALLO Trial."
Status: Active (not recruiting), Estimated PCD: 2023-12-05
Clinical trial
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Status: Terminated, Estimated PCD: 2021-06-30
Product
IGF/MTX
Clinical trial
A Phase Ib/II, Single Center, Open-Label, Safety and Efficacy Study to Improve Anemia in Subjects on Enasidenib With Lower Risk Myelodysplastic Syndrome and Non-proliferative Chronic Myelomonocytic Leukemia Without an IDH2 Mutation
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Enasidenib mesylat
Drug
ifosfamide
Drug
FOLFOXIRI
Clinical trial
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission
Status: , Estimated PCD: 2006-12-01
Product
asparaginase
Clinical trial
A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies
Status: Completed, Estimated PCD: 2023-09-30
Product
CAR-37
Clinical trial
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Status: Active (not recruiting), Estimated PCD: 2026-12-01
Product
Therapeutic autologous lymphocytes
Clinical trial
Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia
Status: , Estimated PCD: 2005-11-01
Clinical trial
Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia
Status: Terminated, Estimated PCD: 2018-12-12
Product
CART 19
Clinical trial
CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Completed, Estimated PCD: 2021-03-08
Product
DLI
Clinical trial
Phase II Study of Campath-1H (NSC #950010) and Peripheral Blood Stem Cell Transplant for Patients With Chronic Lymphocytic Leukemia
Status: , Estimated PCD: 2004-12-01
Clinical trial
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Status: Completed, Estimated PCD: 2023-07-17
Product
ALRN-6924
Clinical trial
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia
Status: Terminated, Estimated PCD: 2010-12-01
Clinical trial
A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation
Status: Completed, Estimated PCD: 2011-01-01
Product
clofarabine
Product
Reverse Transcriptase-Polymerase Chain Reaction
Clinical trial
A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies
Status: Completed, Estimated PCD: 2019-07-09
Clinical trial
Assessment of Novel Molecular Markers in Acute Myeloid Leukemia
Status: , Estimated PCD: 2015-12-01
Product
DNA methylation analysis
Clinical trial
Zanubrutinib and Venetoclax as Initial Therapy for CLL With Obinutuzumab Consolidation in Patients With Minimal Residual Disease Positivity (BruVenG)
Status: Recruiting, Estimated PCD: 2025-01-01
Drug
Zanubrutinib
Clinical trial
A Phase Ib to Investigate the CD123-targeted DART Flotetuzumab Following Allogeneic Transplant for Patients With CD123+ Acute Myeloid Leukemia
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Flotetuzumab
Clinical trial
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Palifermin
Drug
LHRH agonist
Product
Degarelix
Product
MEC
Clinical trial
The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
Status: Withdrawn, Estimated PCD: 2022-03-04
Product
BMS-986414
Product
BMS-986413
Clinical trial
A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion
Status: Active (not recruiting), Estimated PCD: 2014-06-20
Product
PCI 32765
Clinical trial
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Status: Completed, Estimated PCD: 2009-03-01
Product
Gemtuzumab ozogamicin
Clinical trial
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma
Status: Not yet recruiting, Estimated PCD: 2031-06-01
Clinical trial
Precision Medicine for Every Child With Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Whole Genome Sequencing
Product
RNA seq
Product
DNA Methylation
Product
Targeted Panel Sequencing
Product
High Throughput Sequencing
Product
Patient Derived Xenograft
Clinical trial
Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL）
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Olverembatinib
Clinical trial
A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AML
Status: Active (not recruiting), Estimated PCD: 2026-11-30
Product
Cytokine-Induced Memory-like Natural Killer Cells
Clinical trial
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06.
Status: Withdrawn, Estimated PCD: 2004-04-07
Product
Amifostine
Product
Cyclosporin
Clinical trial
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Status: Recruiting, Estimated PCD: 2031-03-31
Product
Luspatercept
Clinical trial
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma
Status: Active (not recruiting), Estimated PCD: 2018-11-14
Product
CD22-specific CAR T-cells with EGFRt
Clinical trial
A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Status: Completed, Estimated PCD: 2017-12-01
Product
BEZ235
Clinical trial
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status: Active (not recruiting), Estimated PCD: 2022-07-18
Product
palifermin
Clinical trial
Combination of Nivolumab and Ipilimumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Completed, Estimated PCD: 2016-01-01
Clinical trial
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Status: Recruiting, Estimated PCD: 2033-06-27
Product
Nemtabrutinib
Clinical trial
A Phase I/II Trial of MB-dNPM1-TCR.1 in HLA-A*02:01-positive Patients With Relapsed or Refractory NPM1-mutated AML to Determine Safety and Obtain First Data on Efficacy
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Product
MB-dNPM1-TCR.1
Clinical trial
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CD22CART
Clinical trial
A Phase 1 Study in Patients With Hematological Malignancies to Evaluate Safety, Tolerability and Efficacy of Karonudib
Status: Recruiting, Estimated PCD: 2026-01-30
Product
Karonudib
Clinical trial
Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells
Status: Completed, Estimated PCD: 2023-05-31
Product
CD7 CART
Clinical trial
A Single Arm, Open-labelled Phase II Clinical Trial of Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) for Treatment of B-cell Haematological Malignancies
Status: Recruiting, Estimated PCD: 2026-12-31
Product
CUCART19